Pilot study of SGN-15 immunoconjugate with docetaxel as first line therapy for NSCLC with PET assessment of response

@article{McDonald2005PilotSO,
  title={Pilot study of SGN-15 immunoconjugate with docetaxel as first line therapy for NSCLC with PET assessment of response},
  author={M. McDonald and M. Rarik and C. Rudin and R. Wahl and J. Vansant and J. Leal and L. Grove and D. Miller and H. Ross},
  journal={Journal of Clinical Oncology},
  year={2005},
  volume={23},
  pages={7299-7299}
}
  • M. McDonald, M. Rarik, +6 authors H. Ross
  • Published 2005
  • Medicine
  • Journal of Clinical Oncology
    • 7299 Background: NSCLC cells express tumor antigens, including Lewis Υ (Ley). SGN-15 is a novel antibody-drug conjugate that delivers doxorubicin to cells expressing Ley and has synergistic activity with docetaxel (Doc) based on cell cycle specificity. A randomized phase II study in second and third line NSCLC showed promising activity of SGN-15+Doc. Preclinical studies show that the sequence of SGN-15+Doc can be adjusted to maximize activity and form the basis for this pilot front-line study… CONTINUE READING
    View via Publisher